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ORIGINAL ARTICLE
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ABSTRACT
Objectives: Despite recombinant interferon-k 4 (IFN-k4) demonstrating anti-viral activity in vitro and
the ancestral functional gene (IFNL4) being conserved in all other primates, there has been speculation
that IFN-k4 may be detrimental in humans. In light of recent rekindled interest in humoral immunity,
this study aimed at evaluating the impact of baseline characteristics, including IFNL4, on antibody lev-
els to hepatitis C virus (HCV).
Materials and methods: Pretreatment sera from 279 well-characterized North European Caucasians
with chronic HCV genotype 2 or 3 infection having undergone liver biopsy were analyzed regarding
IFNL4 (rs12979860) and anti-HCV antibody levels using a commercially available assay.
Results: Patients producing IFN-k4 had higher signal to cut-off (S/CO) anti-HCV antibody ratios as
compared with those lacking IFN-k4 (IFNL4rs12979860 CT/TT versus CC, p<.0001, Mann–Whitney U-test).
Additionally, in univariate analyses S/CO was significantly higher in men than women (p<.001), as well
as in patients with absent/mild interface hepatitis (Ishak grade 0–2 versus 3–4, p¼ .009), and absent/
mild steatosis (grade 0–1 versus 2–3, p¼ .0005). Also, an inverse correlation with HCV RNA level
(rs¼0.14, p¼ .02) was noted. In multivariate analysis IFN-k4, gender, steatosis and viral load
remained independently associated.
Conclusions: To our knowledge, this is the first report that demonstrates that the ability to produce
IFN-k4, in addition to male gender, absent/mild steatosis, and lower viral load, augments antibody lev-
els against HCV. This indicates that IFN-k4 may be associated with T helper cell 2 (Th2) immune skew-
ing, which might have clinical implications beyond HCV infection.
ClinicalTrials.gov Identifier: NCT00143000
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Introduction
Homozygous carriage of the C allele in rs12979860 in the
proximity of the interleukin 28B gene (IL28B also known as
interferon-k 3 (IFNL3)) on chromosome 19 substantially
increases the likelihood of spontaneous clearance of acute
hepatitis C virus (HCV) infection [1] as well as improved out-
come following interferon-based HCV therapy [2,3]. Recently,
however, this single-nucleotide polymorphism (SNP) was
found to be located in intron 1 in a novel, previously over-
looked gene encoding interferon-k4 (IFNL4), and to be in
strong linkage disequilibrium (LD) with an insertion/deletion
polymorphism in IFNL4 exon 1 (rs368234815). Humans are
polymorphic for the dinucleotide TT/DG allele in
rs368234815 [4], with the TT allele resulting in a frameshift
which leads to pseudogenization of IFNL4 and nullification of
IFN-k4 production. In contrast, the ancestral wild-type allele
DGrs368234815, which is present in all non-human primates [5],
allows for production of IFN-k4.
IFN-k4 is the most divergent member of the IFN-k family
and has only 29% amino acid identity with IFN-k3, unlike the
>80% homology observed between IFN-k1, IFN-k2 and
IFN-k3 [4]. Recombinant IFN-k4 signals through the IFN-k
receptor 1 [6] to activate the JAK/STAT pathway, which sub-
sequently induces expression of interferon-stimulated genes
(ISGs). This in turn leads to high anti-viral activity, although
the amino acid substitution K154 fixed throughout evolution
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in hominid lineages reduces the secretion and potency of
IFN-k4 in comparison to the ancestral E154 found in IFN-k4
in chimpanzee and other mammals [7].
IFN-k4 expression in vitro in human hepatic cells (HepG2
and primary human hepatocytes (PHHs)) results in significant
intracellular retention of IFN-k4, reduced proliferation,
increased cell death, but also in strong activation of ISGs in
surrounding cells [8]. Also, IFN-k4 induction in Huh-7, HepG2
and PHHs cells leads to interferon-a unresponsiveness by
upregulating levels of ISG15 and ubiquitin specific peptidase
18 (USP18) [9].
Aside from impacting on HCV infection, abrogation of
IFN-k4 is also associated with more severe steatosis (Kleiner
grade 3), lobular inflammation (grade 2–3), and hepatic fibro-
sis (stage F3–F4) in nonalcoholic fatty liver disease (NAFLD)
and nonalcoholic steatohepatitis (NASH) especially among
nonobese individuals [10]. Similarly, inability to produce IFN-
k4 is associated with increased risk of some autoimmune dis-
orders, e.g., lupus nephritis in systemic lupus erythematosus
(SLE) [11] and pulmonary fibrosis in systemic sclerosis (aka
scleroderma) [12], as well as with lower frequencies of regu-
latory T cells (Treg) in colonic tissue biopsies [13].
Several studies have focused on IFN-k4 and impaired
adaptive and innate immunity [14,15], and unexpectedly
there is scant in vivo evidence of potential benefits of having
a functional IFNL4 gene aside from lower risk of some auto-
immune diseases, despite being highly conserved in other
primates. In light of this as well as renewed interest in
humoral immunity, this study aimed at evaluating the impact
of IFNL4 variants on anti-HCV antibody levels using a com-
mercially available assay in a well-characterized cohort of
North European Caucasian patients with chronic HCV geno-
type 2 or 3 infection having undergone liver biopsy.
Materials and methods
Study population
Three hundred eighty-two genotype 2 or 3 infected patients
were enrolled in the NORDynamIC trial [16] and previously
genotyped for IFNL4rs12979860 [17]. Pretreatment sera from
279 of these well-characterized patients of North European
Caucasian origin (baseline characteristics summarized in
Table 1) could be retrieved and analyzed for anti-HCV anti-
body responses in this study.
Anti-HCV antibody detection
All samples were analyzed using the chemiluminescent
microparticle immunoassay on the Alinity instrument
(Abbott, Chicago, IL) in accordance with the manufacturer’s
instructions. The assay measures the amount of anti-HCV
antibodies against the recombinant HCV proteins HCr43
expressed in Escherichia coli (prepared by Chiron
Corporation, Emeryville, CA), containing amino acids 1–150
in core and 1192–1457 (33c) in NS3, and c100-3 expressed in
Saccharomyces cerevisiae (prepared by Chiron Corporation,
Emeryville, CA), containing amino acids 1569-1931 in NS3,
NS4a and NS4b. The chemiluminescent reaction is measured
as relative light units (RLUs) detected by the system optics,
and there is a direct relationship between the amount of
anti-HCV in the sample and RLUs. A signal-to-cutoff ratio (S/
CO) is determined by comparing the chemiluminescent RLUs
in the reaction to the cutoff RLUs determined from an active
calibration, and S/CO 1.0 is considered reactive. All sera
were stored at 80 C until analyzed.
IFNL4 genotyping
Rs12979860 polymorphisms in chromosome 19 were deter-
mined in serum by allelic discrimination using Taq-Man SNP
Assays (Life Technologies, Carlsbad, CA) using an in-house
test as described previously [17].
HCV-RNA detection and genotyping
All HCV RNA samples were analyzed by Roche COBAS
AmpliPrep/COBAS TaqMan HCV test as described by the
manufacturer.




Age (years), mean (SD) 42.8 (10.7)
Sex (male), n (%) 164 (58.8)
BMI (kg/m2), mean (SD) 25.9 (4.2)
Characteristics of HCV infection
HCV-RNA at baseline (log10 IU/mL), mean (SD) 6.0 (0.9)
HCV genotype (genotype 2/3/2þ 3), n (%) 83/194/2 (29.7/69.5/0.7)
Ishak fibrosis stage (0/1/2/3/4/5/6), n 7/32/73/65/37/15/25
Cirrhosis, n (%) 40 (14.3)
Ishak interface hepatitis grade (0/1/2/3/4), n 12/81/93/63/5
Ishak lobular inflammation grade (0/1/2/3/4), n 1/51/156/44/2
Ishak portal inflammation grade (0/1/2/3/4), n 10/114/107/23/0
Steatosis grade (0/1/2/3), n 85/102/45/22
Anti-HCV S/CO ratio, AU (SD) 13.0 (2.7)
Host genetics
IFNL4 rs12979860 T allele carrier yes/no (%) 157/122 (56%)
HCV: hepatitis C virus; SD: standard deviation; SVR: sustained virologic response.
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Liver biopsies
Liver biopsies were obtained from all patients within
12months prior to study entry. The evaluation was per-
formed in a blinded fashion according to the Ishak protocol
[18]. Additionally steatosis was graded [19].
Statistical analyses
Mann–Whitney U test was used when comparing the amount
of anti-HCV antibodies between groups. Logistic regression
was applied after dichotomization of anti-HCV antibodies
above or below study median. All parameters with a p-value
above .1 in the univariate analysis was included in the multi-
variate analysis after checking for multicollinearity. Statistics
was done in Prism (Version 9.0.1, GraphPad Software, La
Jolla, CA) or SPSS (Version 27, IBM Corp, Armonk, NY) soft-
ware. All reported p values are two-sided, and p values <.05
were considered significant.
Ethical considerations
Written informed consent was obtained from each participat-
ing patient, and ethics committees in each participating
country approved the study. The study has been registered
at the NIH trial registry (ClinicalTrials.gov Identifier:
NCT00143000).
Results
IFNL4 and anti-HCV antibody level
A highly significant relationship between IFNL4rs12979860
genotype and S/CO antibody level was observed (Figure
1(A)), with the lowest antibody levels (S/CO) observed in the
absence of IFN-k4 (IFNL4rs12979860 CC genotype) as compared
to one (IFNL4rs12979860 CT) or 2 functional IFNL4 genes
(IFNL4rs12979860 TT).
As IFNL4rs12979860 genotype is known to associate with
interferon gamma-induced protein 10 (IP-10 aka CXCL10)
[20], the correlation between IP-10 and S/CO was also
explored, and a non-significant trend was noted towards
higher anti-HCV antibody levels when IP-10 concentrations
were lower (p¼ .06).
As IFNL4rs12979860 genotype is known to associate with
sustained virologic response (SVR) following interferon and
ribavirin combination therapy for HCV, the correlation
between SVR and S/CO was evaluated but was not
significant.
Gender and anti-HCV antibody level
A marked gender difference in antibody levels was noted,
with significantly higher S/CO in men as compared to
women (p<.0001; Figure 1(B)). For both gender the ability to
produce IFN-k4 entailed significantly higher antibody levels
(Figure 1(C)).
Histopathology and anti-HCV antibody level
Significantly higher S/CO antibody levels were observed
among patients with absent/mild interface hepatitis (Ishak
grade 0–2 versus 3–4, p ¼ .009; Figure 2A) and absent/mild
steatosis (grade 0–1 versus 2–3, p ¼ .0005; Figure 2B). As
body mass index (BMI) and HCV genotype 3 infection are
known to associate with steatosis [19], their associations with
anti-HCV S/CO were evaluated but were not significant
(Table 2). A non-significant trend was noted towards lower
antibody levels in patients with significant fibrosis (Ishak
stage 0–2 versus 3–6 median 13.9 versus 13.0 respectively,
p ¼ .06). Please note, however, that when using univariate
logistic regression this association was significant (p ¼ .02;
Table 2).
Figure 1. Signal-to-cutoff (S/CO) antibody ratio in relation to the absence of IFN-k4 (IFNL4rs12979860 CC) or presence of IFN-k4 (IFNL4rs12979860 CT/TT) (A), gender (B),
and gender and IFN-k4 (C). Median and interquartile range. Statistics using Mann–Whitney U test.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY 851
HCV RNA concentration and anti-HCV antibody level
An inverse correlation with HCV RNA level (rs¼0.14,
p¼ .02) was noted. Although HCV RNA previously has been
reported to be significantly higher in genotype 3 infected
patients lacking IFN-k4 (IFNL4rs12979860 CC genotype) as com-
pared those with a functional gene (IFNL4rs12979860 CT/TT)
enrolled in the NORDynamIC trial [17], no significant differen-
ces in anti-HCV S/CO between patients infected with geno-
types 2 and 3 were observed (Table 2).
Multivariate analysis and anti-HCV antibody level
Parameters associated with an anti-HCV S/CO value above or
below study median were evaluated using logistic regression.
IFN-k4 genotype, gender, steatosis and viral load remained inde-
pendently associated with the anti-HCV S/CO value (Table 2).
Discussion
The main findings of this study were that ability to produce
IFN-k4, in addition to male gender, absent/mild steatosis,
and lower viral load, augmented antibody responses against
HCV, and that highest antibody ratios were observed in car-
riers with two functional genes (IFNL4rs12979860 TT homozy-
gotes) in both genders. To our knowledge, this is the first
study to demonstrate that the ability to produce IFN-k4 is
associated with higher antibody levels against HCV.
Despite recombinant IFN-k4 being highly antiviral in vitro
[7], and signaling through the IFN-k receptor 1 to activate
the JAK/STAT pathway and subsequently inducing expression
of ISGs, the ability to produce IFN-k4 in vivo is predictive of
inferior likelihood of spontaneous resolution of acute HCV
infection [1] and unresponsiveness to interferon and ribavirin
combination treatment [2,3]. Members of the IFN-k family
generally tend to favor a Th1 skewed immune response, i.e.,
greater activation of macrophages, cytotoxic T cells and NK
cells as well as less stimulation of antibody producing B cells.
However, data on IFN-k4, which is the most divergent mem-
ber of the interferon-k family [4], are scarcer in this regard
[21]. Interestingly, following immunization of 91 kidney, 64
lung, 24 liver and 17 heart transplant recipients on mainten-
ance immunosuppression enrolled in a trial of intradermal
versus intramuscular influenza vaccine, increased rates of
Figure 2. Signal-to-cutoff (S/CO) antibody ratio in anti-HCV antibody assay in relation to absent/mild or moderate/severe interface hepatitis (Ishak grade
0–2 versus 3–4) (A), and absent/mild or moderate/severe steatosis (grade 0–1 versus 2–3) (B). Median and interquartile range. Statistics using Mann-
Whitney U-test.
Table 2. Associations of baseline characteristics with anti-HCV S/CO ratio.
Univariate logistic regression Logistic regression
OR 95% CI p Value OR 95% CI p Value
Epidemiological features
Age (years) 0.97 0.95–0.99 .01 0.99 0.96–1.02 .56
Sex (female) 0.33 0.20–0.54 <.001 0.19 0.10–0.36 <.001
BMI (kg/m2) 1.02 0.96–1.08 .6
Characteristics of HCV infection
HCV-RNA at baseline (log10 IU/mL) 0.65 0.49–0.87 .003 0.62 0.43–0.88 .008
HCV genotype (genotype 2/3) 0.96 0.57–1.6 .87
Ishak fibrosis stage 0.82 0.79–0–97 .02 0.88 0.67–1.15 .35
Ishak inflammation grade (sum of score) 0.86 0.75–0.98 .02 0.96 0.78–1.18 .67
Steatosis grade 0.70 0.53–0.92 .01 0.70 0.51–0.96 .03
Host genetics
IFNL4 rs12979860 CC carrier yes/no (%) 0.42 0.26–0.68 <.001 0.51 0.29–0.89 .02
Significant values are highlighted in bold.
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seroconversion (i.e., 4-fold rise in titer from pre-vaccination
to at least one of the three vaccine antigens) were noted in
individuals capable of producing IFN-k4 (IFNL4rs8099917 TG/
GG) [22], although the ethnic and racial background of the
study population was not reported. Similarly, carriage of the
minor G allele in rs10853727 located within IFNL4 has been
associated with significantly higher antibody titers following
measles vaccination in racially and ethnically diverse pediat-
ric populations in two independent studies [23,24], although
the impact of this particular SNP on expression or function
of IFN-k4 remains unclear. Together these previous studies
support the observation noted in the present study that abil-
ity to produce of IFN-k4 entails improved antibody respon-
siveness. However, the present study extends upon these
findings as it excludes the potential confounding effect of
ethnic and racial background, which are known to impact on
many aspects of vaccine efficacy [25].
The finding in this study suggesting that presence of IFN-
k4 predisposes towards a Th2-skewed immune response is
intriguing and may indicate a shift from B- to T-cell respon-
siveness in humans following evolutionary pressure.
Interestingly, the frameshift mutation in IFNL4 that rescinds
IFN-k4 production has been suggested to have appeared in
homo sapiens just prior to the out-of-Africa migration, and
thereafter enriched by positive selection [26]. It is, thus,
tempting to hypothesize that in smaller, isolated hunter–
gatherer societies where exposure to epidemic pathogens is
unlikely, Th2 responses may have greater importance, for
example, stronger maternal antibody responses against
enteric and endemic pathogenic microorganisms leading to
reduce infant mortality. In contrast, after marked population
growth occurred following the development of agriculture
and domestication of animals in the Neolithic Revolution and
subsequent urbanization, the introduction and spread of
novel zoonic epidemic infectious agents was greatly facili-
tated, selecting for enhanced Th1 responsiveness by reduc-
ing or annulling the production of IFN-k4.
The observation in the present study that antibody ratios
were significantly higher in men than in women is in line
with well-documented gender differences in immune
responses observed in numerous vaccine trials [27], as well
as following SARS-CoV-2 infection [28].
The impact of hepatic histopathology on antibody levels
is noteworthy, and, to our knowledge, the highly significant
association with steatosis has not previously been reported.
In univariate analysis, interface hepatitis was also significant,
but in multivariate analysis, steatosis grade was the only
aspect of liver histopathology that remained independent
associated with antibody levels, with more pronounced stea-
tosis being linked with significantly lower antibody levels.
This was somewhat surprising as neither body mass index
(BMI) nor HCV genotype 3 infection, which both are known
to associate with steatosis [19], were not significantly associ-
ated with anti-HCV antibody levels. Interestingly, obesity is
reported to be associated with a heightened state of
immune activation as exemplified by elevated antibody titers
to heat-shock protein-27 [29], which additionally controverts
the notion that higher BMI was driving the association
between steatosis and antibody levels observed in this study.
The inverse correlation between anti-HCV antibody ratios
and HCV RNA level was expected as baseline HCV RNA levels
are reportedly elevated in the absence of IFN-k4
(IFNL4rs12979860 CC) [17]. However, in the multivariate analysis,
both viral load and IFNL4 genotype were independently
associated with anti-HCV antibody levels.
In conclusion, the present study demonstrated that IFNL4
genetic variants resulting in ability to produce IFN-k4 are
linked with elevated anti-HCV antibody levels. This finding
implies that IFN-k4 may impact on host antibody responses
and warrants further investigation as this likely has clinical
implications beyond HCV, e.g., levels of antibody against
other viruses.
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